Assetmark Inc. trimmed its position in Zoetis Inc (NYSE:ZTS) by 1.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 79,014 shares of the company’s stock after selling 1,245 shares during the period. Assetmark Inc.’s holdings in Zoetis were worth $7,235,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Sun Life Financial INC raised its holdings in shares of Zoetis by 604.3% in the second quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock worth $112,000 after buying an additional 1,124 shares during the last quarter. Signature Estate & Investment Advisors LLC purchased a new position in shares of Zoetis in the third quarter worth $112,000. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Zoetis by 3,033.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after buying an additional 1,365 shares during the last quarter. Fort L.P. purchased a new position in shares of Zoetis in the second quarter worth $121,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Zoetis in the third quarter worth $146,000. Institutional investors own 89.94% of the company’s stock.

In other Zoetis news, insider Kristin C. Peck sold 11,500 shares of Zoetis stock in a transaction on Monday, November 12th. The shares were sold at an average price of $94.78, for a total value of $1,089,970.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction on Monday, October 1st. The shares were sold at an average price of $92.03, for a total transaction of $184,060.00. The disclosure for this sale can be found here. Insiders sold 169,511 shares of company stock valued at $16,081,299 in the last ninety days. 0.35% of the stock is owned by corporate insiders.

ZTS opened at $88.09 on Friday. Zoetis Inc has a fifty-two week low of $70.20 and a fifty-two week high of $96.57. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. The firm has a market capitalization of $43.51 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 1.79 and a beta of 0.99.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The company had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter in the previous year, the company earned $0.65 earnings per share. The firm’s revenue for the quarter was up 9.9% on a year-over-year basis. As a group, equities analysts anticipate that Zoetis Inc will post 3.11 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Tuesday, November 20th were issued a $0.126 dividend. The ex-dividend date of this dividend was Monday, November 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.57%. Zoetis’s payout ratio is 20.83%.

ZTS has been the subject of several recent research reports. BMO Capital Markets reissued a “hold” rating on shares of Zoetis in a report on Sunday, November 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $105.00 target price (up previously from $98.00) on shares of Zoetis in a report on Wednesday, October 17th. Argus set a $105.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Tuesday, November 13th. JPMorgan Chase & Co. raised their target price on shares of Zoetis from $100.00 to $101.00 and gave the stock an “overweight” rating in a report on Friday, November 2nd. Finally, Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $101.00 target price for the company in a report on Monday, September 10th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $94.00.

TRADEMARK VIOLATION WARNING: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.dailypolitical.com/2018/12/08/zoetis-inc-zts-holdings-trimmed-by-assetmark-inc.html.

Zoetis Company Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Recommended Story: Should you buy a closed-end mutual fund?

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.